See more : Prime Mining Corp. (PRYM.TO) Income Statement Analysis – Financial Results
Complete financial analysis of ApicHope Pharmaceutical Co., Ltd (300723.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ApicHope Pharmaceutical Co., Ltd, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Build King Holdings Limited (0240.HK) Income Statement Analysis – Financial Results
- Lianhe Chemical Technology Co., Ltd. (002250.SZ) Income Statement Analysis – Financial Results
- EFG International AG (0QJX.L) Income Statement Analysis – Financial Results
- Piaggio & C. SpA (PIA.MI) Income Statement Analysis – Financial Results
- Cimarex Energy Co. (0HYB.L) Income Statement Analysis – Financial Results
ApicHope Pharmaceutical Co., Ltd (300723.SZ)
About ApicHope Pharmaceutical Co., Ltd
ApicHope Pharmaceutical Co., Ltd, together with its subsidiaries, engages in the research and development, production, and sale of pharmaceutical products. It offers anti-infection, pediatric, cardiovascular, genitourinary, respiratory, liver and digestion, and dermatological products, as well as anti-inflammatory and analgesic products. The company was formerly known as Yipinhong Pharmaceutical Co.,Ltd and changed its name to ApicHope Pharmaceutical Co., Ltd in December 2021. ApicHope Pharmaceutical Co., Ltd was founded in 2002 and is based in Guangzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.50B | 2.28B | 2.20B | 1.68B | 1.64B | 1.43B | 1.38B | 1.25B | 1.03B | 792.55M | 507.57M |
| Cost of Revenue | 474.58M | 300.20M | 318.46M | 295.43M | 367.03M | 393.47M | 579.91M | 599.39M | 478.77M | 391.44M | 316.61M |
| Gross Profit | 2.03B | 1.98B | 1.88B | 1.38B | 1.27B | 1.04B | 800.31M | 651.45M | 549.53M | 401.12M | 190.95M |
| Gross Profit Ratio | 81.04% | 86.83% | 85.52% | 82.37% | 77.58% | 72.48% | 57.98% | 52.08% | 53.44% | 50.61% | 37.62% |
| Research & Development | 301.37M | 189.78M | 142.32M | 135.34M | 98.05M | 91.38M | 81.07M | 46.97M | 30.56M | 40.32M | 18.49M |
| General & Administrative | 131.89M | 64.08M | 52.51M | 18.88M | 28.09M | 29.89M | 25.78M | 14.48M | 44.88M | 11.80M | 36.08M |
| Selling & Marketing | 1.12B | 1.25B | 1.28B | 934.46M | 851.11M | 614.08M | 439.48M | 371.63M | 328.30M | 245.88M | 100.77M |
| SG&A | 1.26B | 1.31B | 1.33B | 953.34M | 879.20M | 643.97M | 465.26M | 386.12M | 373.18M | 257.68M | 136.85M |
| Other Expenses | 258.18M | 31.97M | 101.45M | 74.74M | 6.79M | 8.88M | 3.35M | 22.68M | 1.63M | 2.23M | -375.99K |
| Operating Expenses | 1.81B | 1.65B | 1.60B | 1.18B | 1.04B | 796.66M | 596.52M | 488.86M | 444.52M | 326.10M | 140.20M |
| Cost & Expenses | 2.29B | 1.95B | 1.92B | 1.48B | 1.41B | 1.19B | 1.18B | 1.09B | 923.29M | 717.54M | 456.81M |
| Interest Income | 10.45M | 8.46M | 7.46M | 1.89M | 1.26M | 1.05M | 308.52K | 238.70K | 10.94M | 366.54K | 0.00 |
| Interest Expense | 37.65M | 24.45M | 38.51M | 11.75M | 5.39M | 17.41M | 15.49M | 18.27M | 32.53M | 20.30M | 6.97M |
| Depreciation & Amortization | 182.20M | 113.52M | 84.41M | 41.52M | 38.01M | 36.05M | 33.57M | 31.44M | 28.37M | 17.63M | 13.39M |
| EBITDA | 464.04M | 448.32M | 498.78M | 326.85M | 232.63M | 297.28M | 234.18M | 214.00M | 143.48M | 92.97M | 64.14M |
| EBITDA Ratio | 18.54% | 19.75% | 21.62% | 19.61% | 17.31% | 21.55% | 17.45% | 17.34% | 14.19% | 11.98% | 12.39% |
| Operating Income | 213.93M | 281.97M | 285.28M | 198.55M | 182.27M | 234.83M | 181.70M | 141.80M | 80.82M | 52.86M | 43.71M |
| Operating Income Ratio | 8.55% | 12.37% | 12.97% | 11.85% | 11.13% | 16.43% | 13.16% | 11.34% | 7.86% | 6.67% | 8.61% |
| Total Other Income/Expenses | 30.25M | 44.44M | 77.49M | 74.74M | 6.79M | 8.88M | 3.35M | 22.39M | 1.45M | 2.18M | -396.92K |
| Income Before Tax | 244.19M | 326.41M | 362.77M | 273.30M | 189.06M | 243.71M | 185.04M | 164.19M | 82.27M | 55.04M | 43.31M |
| Income Before Tax Ratio | 9.75% | 14.32% | 16.50% | 16.31% | 11.55% | 17.05% | 13.41% | 13.13% | 8.00% | 6.94% | 8.53% |
| Income Tax Expense | 92.39M | 64.32M | 69.36M | 49.66M | 46.53M | 36.02M | 30.23M | 28.35M | 21.87M | 15.84M | 10.99M |
| Net Income | 184.61M | 290.68M | 306.92M | 225.61M | 143.69M | 208.22M | 156.70M | 137.35M | 60.42M | 40.31M | 32.99M |
| Net Income Ratio | 7.37% | 12.75% | 13.96% | 13.47% | 8.78% | 14.57% | 11.35% | 10.98% | 5.88% | 5.09% | 6.50% |
| EPS | 0.42 | 0.69 | 0.71 | 0.52 | 0.33 | 0.48 | 0.47 | 0.42 | 0.19 | 0.00 | 0.00 |
| EPS Diluted | 0.42 | 0.69 | 0.71 | 0.52 | 0.33 | 0.48 | 0.47 | 0.42 | 0.19 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 439.56M | 420.83M | 430.26M | 433.87M | 431.06M | 432.00M | 333.13M | 325.30M | 326.27M | 0.00 | 0.00 |
| Weighted Avg Shares Out (Dil) | 439.56M | 420.83M | 430.26M | 433.87M | 431.06M | 435.82M | 333.13M | 325.30M | 326.27M | 0.00 | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports